| Literature DB >> 29509661 |
Zeljka Rupcic1,2, Monique Rascher3,4,5, Sae Kanaki6,7, Reinhard W Köster8, Marc Stadler9,10, Kathrin Wittstein11,12.
Abstract
Basidiomycetes of the genus Hericium are among the most praised medicinal and edible <span class="Disease">mushrooms, which are known to produce secondary metabolites with the potential to treat neurodegenerative diseases. This activity has been attributed to the discovery of various terpenoids that can stimulate the production of nerve growth factor (NGF) or (as established more recently) brain-derived neurotrophic factor (BDNF) in cell-based bioassays. The present study reports on the metabolite profiles of a Lion's Mane mushroom (Hericium erinaceus) strain and a strain of the rare species, Hericium flagellum (synonym H. alpestre). While we observed highly similar metabolite profiles between the two strains that were examined, we isolated two previously undescribed metabolites, given the trivial names erinacines Z1 and Z2. Their chemical structures were elucidated by means of nuclear magnetic resonance (NMR) spectroscopy and high resolution mass spectrometry. Along with six further, previously identified cyathane diterpenes, the novel erinacines were tested for neurotrophin inducing effects. We found that erinacines act on BDNF, which is a neurotrophic factor that has been reported recently by us to be induced by the corallocins, but as well on NGF expression, which is consistent with the literature.Entities:
Keywords: Basidiomycota; fermentation; fungal metabolites; natural products; neurotrophic activity
Mesh:
Substances:
Year: 2018 PMID: 29509661 PMCID: PMC5877601 DOI: 10.3390/ijms19030740
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Comparison of secondary metabolites isolated from the cultures of H. erinaceus and H. flagellum.
| Compounds | ||
|---|---|---|
| Erinacine Z1 ( | + | − |
| Erinacine Z2 ( | − | + |
| Erinacine A ( | + | + |
| Erinacine B ( | + | + |
| Erinacine C ( | + | + |
| Erinacine E ( | + | + |
| CJ14.258 ( | − | + |
| Erinacine F ( | − | + |
Figure 1Chemical structures of the isolated cyathane diterpenoids (1–8).
1H and 13C NMR data of erinacine Z1 (1; 500 MHz and 125 MHz in CDCl3) and erinacine Z2 (2; 700 MHz and 175 MHz in acetone-d6). Corresponding spectra are deposited in the Supplementary Materials.
| Position | (1) | (2) | ||
|---|---|---|---|---|
| 1 | 38.5, CH2 | 1.46, m; 1.62, m | 38.3, CH2 | 1.54, m |
| 2 | 28.4, CH2 | 2.27, m | 29.1, CH2 | 2.31, m |
| 3 | 139.9, C | 140.7, C | ||
| 4 | 136.6, C | 139.8, C | ||
| 5 | 40.4, CH | 1.93, m | 36.1, CH | 3.47, m |
| 6 | 40.6, C | 44.5, C | ||
| 7a | 30.4, CH2 | 1.32, td (12.2, 6.6) | 34.3, CH2 | 1.16, m |
| 7b | 1.62, m | 2.41, td (13.8, 4.2) | ||
| 8 | 37.0, CH2 | 1.46, m | 37.1, CH2 | 1.44, ddd (12.5, 7.7, 3.0) 1.54, m |
| 9 | 49.2, C | 50.4, C | ||
| 10b | 30.1, CH2 | 1.81, ddd (14.2, 11.9, 5.5) | 35.0, CH2 | 2.07, m |
| 10a | 2.54, dd (13.7, 10.1) | 2.14, m | ||
| 11 | 72.4, CH | 4.63, m | 62.1, CH | 4.78, br d (5.2) |
| 12 | 138.6, C | 148.2, C | ||
| 13 | 158.2, CH | 6.94, dd (5.6, 1.2) | 154.6, CH | 7.01, dd (7.3, 0.9) |
| 14 | 85.4, CH | 4.61, d (5.6) | 85.3, CH | 3.96, d (7.3) |
| 15 | 192.9, CH | 9.54, s | 194.2, CH | 9.43, s |
| 16 | 16.4, CH3 | 0.99, s | 16.4, CH3 | 0.82, s |
| 17 | 24.5, CH3 | 0.93, s | 24.7, CH3 | 1.14, s |
| 18 | 27.0, CH | 2.85, m | 27.7, CH | 3.08, m |
| 19 | 21.5, CH3 | 0.97, d (6.8) | 22.0, CH3 | 0.97, m |
| 20 | 21.8, CH3 | 0.97, d (6.8) | 22.3, CH3 | 0.97, m |
| 21 | 56.6, CH3 | 3.26, s | - | |
| 1′ | 105.3, CH | 4.34, d (7.0) | 106.3, CH | 4.56, d (5.6) |
| 2′ | 73.5, CH | 3.47, m | 74.6, CH | 3.51, m |
| 3′ | 69,6, CH | 3.74, td (8.8, 5.1) | 70.3, CH | 3.51, m |
| 4′ | 75.7, CH | 3.54, dd (8.8) | 73.3, CH | 3.41, dd (7.3, 5.8) |
| 5′ | 65.1, CH2 | 3.29, m | 65.0, CH2 | 3.28, dd (11.8, 7.5) |
Figure 2(a) Important 1H-1H-COSY and 1H-13C-HMBC correlations of erinacine Z1 1; (b) Relevant ROESY correlations of erinacine Z1 1.
Figure 3Morphological differentiation of PC12 cells incubated with erinacines Z1, Z2, A, B, C, E, and CJ14.258 (1–7) (a) or conditioned medium produced by 1321 N1 cells; (b) (−): negative control, no additive; (−) Ethanol: negative control with ethanol; (−) 1321N1 medium: negative control with 1321N1 medium; (+) SGE: positive control with salivary gland extract (contains NGF). Differentiated cells are marked with an arrow; (c) a quantification of analyses with the amount of differentiated cells [%] or neurite length [µm]. Scale bar 100 µm (±SEM; a, p < 0.01; b, p < 0.001; c, p < 0.0001).
Figure 4Semiquantitative RT-PCR analysis for mRNA of (a) nerve growth factor (NGF) and (b) brain-derived neurotrophic factor (BDNF); (a) A significant increase of NGF was observed for several cyathane derivatives tested. Compounds 3, 4, and 7 increased NGF mRNA by two times, compounds 5 increase NGF by 1.6 times, whereas 2 and 6 failed to induce NGF mRNA upregulation; (b) Only 1321N1 incubated with 5 show a significantly higher BDNF mRNA amount when compared to the ethanol control (±SEM; a, p < 0.05).